Sara Kuruvilla
Papers
5
Total Citations
657
H-Index
5
About
Dr. Sara Kuruvilla is a leading clinical researcher in head and neck oncology, whose work has fundamentally shaped the debate on the optimal treatment for oropharyngeal squamous cell carcinoma (OPSCC). Her primary research focus is the comparative effectiveness of primary radiotherapy (RT) versus transoral robotic surgery (TORS) for early-stage disease. Dr. Kuruvilla is best known as the principal investigator of the landmark ORATOR trial, a phase II randomized study that directly compared these two modalities. The trial's initial results, published in 2019 and cited over 450 times, provided critical, high-level evidence on swallowing outcomes and toxicities, challenging assumptions about the superiority of surgery. Her subsequent work, including the final five-year outcomes reported in 2024, continues to provide essential data for clinical decision-making. With a cumulative citation count exceeding 650, Dr. Kuruvilla’s contributions are instrumental in guiding evidence-based practice for patients with HPV-related oropharyngeal cancer, a disease whose incidence has risen dramatically. Her rigorous, randomized approach has set a new standard for comparative effectiveness research in this field.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5